Clinical trials
Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials
Below are recruiting relapsed or refractory multiple myeloma (rrmm) clinical trials, each written for real people, not researchers. We’re tracking 1,249 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT06225505Recruiting
Early detection of triple-negative breast cancer return
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
AvignonAges 18 years+ - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Springdale, ArkansasAges 18 years+ - NCT06158139RecruitingPhase 1
Testing modified immune cells for pancreatic cancer
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06118502Recruiting
Adaptive quit-smoking treatment for early relapse
This trial tests a flexible treatment approach for smokers who want to quit and are at risk of relapsing early. It aims to help you stay smoke-free by adjusting the support you get.
Charleston, South CarolinaAges 21 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT06112067Recruiting
Brain implant for severe mental health conditions
This trial tests a brain implant called deep brain stimulation (DBS) for people with severe mental health conditions that have not improved with usual treatments. The goal is to see if it can reduce symptoms and improve quality of life.
ShanghaiAges 18–65 - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT06060873Recruiting
Using a blood test to find active germ cell tumors
This trial tests whether a blood test called miRNA-371 can detect active germ cell tumors in patients who have had surgery or are being watched. It may help guide treatment decisions without needing extra biopsies or scans.
Birmingham, AlabamaAges 18 years+ - NCT06069141Recruiting
Comparing syphilis treatments for people with HIV
This study compares the standard treatment for early syphilis with a combination that includes an extra antibiotic, to see which is more effective. It is for people living with HIV who have early syphilis.
Hsinchu, TaiwanAges 18 years+ - NCT05236686Recruiting
Surgery to remove upper abdomen lymph nodes for ovarian cancer
This trial studies whether removing lymph nodes in the upper abdomen (hepatoceliac lymph nodes) improves outcomes for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer that has spread to those lymph nodes. It also looks at how this surgery works for people with certain types of relapse, often alongside chemotherapy.
ShanghaiAges 18–75 - NCT05934188Recruiting
Study how gut signals relate to brain aging and diseases
This study looks at how the gut may influence the brain in normal aging and conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis. It may help researchers understand new ways to measure or treat these brain changes over time.
Venice-Lido, VeniceAges 20–90 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Duarte, CaliforniaAges 18 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT05809284Recruiting
Understanding CAR T-cell therapy persistence in young patients with ALL
This study looks at why CAR T-cell therapy stops working in some children and young adults with leukemia. It aims to help doctors understand how to make this treatment last longer.
LondonAges Up to 25 years - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05748171RecruitingPhase 2
Testing inotuzumab for children with early ALL relapse
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
ViennaAges 1–17 - NCT05772637Recruiting
Testing bladder feeling in people with multiple sclerosis
This study checks how your bladder “sensation” works using bladder testing (including urodynamic testing) to better understand MS-related bladder problems. It may help researchers match bladder symptoms to what’s happening inside the bladder.
Paris, Choisir Une RégionAges 18–99 - NCT05772273Recruiting
Test PD-1 drug plus azacitidine and donor cells for AML relapse
This study tests whether combining a PD-1 immune therapy, azacitidine, and low-dose donor lymphocyte infusion (donor immune cells) can treat AML that has come back after a stem cell transplant. It may help some people regain anti-cancer immune activity after relapse.
Suzhou, JiangsuAges Any age
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma (rrmm)?
- Yes. Clin2 currently lists 1,249 recruiting relapsed or refractory multiple myeloma (rrmm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma (rrmm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma (rrmm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.